Microvascular complications of diabetes

Journal of Biological Sciences

Volumn 10, Issue 5, 2010, Pages 411-423

  Behnam Rassouli, M ^a   Ghayour, M B ^b   Ghayour, N ^b  

^a FERDOWSI UNIVERSITY OF MASHHAD   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Choroid plexus; CSF; Diabetes; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMINOGUANIDINE; CYTOKINE; FRUCTOSE; GLUCOSE; GROWTH FACTOR; HEXOSAMINE; LIPID; POLYOL; POTASSIUM; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SODIUM; SORBITOL; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALBUMINURIA; APOPTOSIS; ARTICLE; AUTONOMIC NEUROPATHY; BLINDNESS; BLOOD RETINA BARRIER; CAPILLARY FLOW; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CIRCULATION DISORDER; CHOROID PLEXUS; DIABETIC MACULAR EDEMA; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOCOMPETENT CELL; INSULIN DEPENDENT DIABETES MELLITUS; ION TRANSPORT; LIPID BLOOD LEVEL; LUNG DISEASE; LUNG FIBROSIS; MICROANEURYSM; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NERVE INJURY; PROTEINURIA; RETINA MACULA EDEMA;

EID: 77954768919     PISSN: 17273048     EISSN: 18125719     Source Type: Journal    
DOI: 10.3923/jbs.2010.411.423     Document Type: Article

References (192)

1. Abi-Chahin, T.C., M.A. Hausen, CM. Mansano-Marques and V.L.R. de Castro Halfoun, 2009. Microvascular reactivity in type 1 diabetics. Arq Bras Endocrinol. Metab.,53: 741-746.
2. Accili, D. and K.C. Arden, 2004. FoxOs at the crossroads of cellular metabolism, differentiation and transformation. Cell, 117: 421-426.
3. Adamis, A.P., J.W. Miller, M.T. Bernal, D.J. D'Amico and J. Folkmanet al., 1994. Elevated vascular permeability factor/vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Ophthalmology, 118: 445-450.
4. Aiello, L.P., R.L. Avery, P.G. Arngg, B.A. Keyt and H.D. Jampel et al., 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med., 331: 1480-1487.
5. Aiello, L.M., 2003. Perspectives on diabetic retinopathy. Am. J. Ophthalmol., 136: 122-135.
6. Alberti, K.G. and P.Z. Zimmet, 1998. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med., 15: 539-553.
7. Algenstaedt, P., C. Schaefer, T. Biermann, A. Hamann and B. Schwarzlohet al., 2003. Microvascular alterations in diabetic mice correlate with level of hyperglycemia. Diabetes, 52: 542-549.
8. Ali, R.A., 2003. Management of diabetic neuropathy. Malaysian J. Med. Sci., 10: 27-30.
9. American Diabetes Association, 2007. Standards of medical care in diabetes-2007. Diabetes Care, 30: 4-41.
10. Asanuma, Y., S. Fujiya, H. Ide and Y. Agishi, 1985. Characteristics of pulmonary function in patients with diabetes mellitus. Diabetes Res. Clin. Pract, 1: 95-101.
11. Bakris, G.L., M. Williams, L. Dworkin, W.J. Elliott, M. Epstein and R. Toto et al., 2000. Preserving renal function in adults with hypertension and diabetes a consensus approach national kidney foundation hypertension and diabetes executive committee working group. Am. J. Kidney Dis., 36: 646-661.
12. Balasubramanyam, M., M. Rema and C. Premanand, 2002. Biochemical and molecular mechanisms of diabetic retinopathy. Current Sci., 83: 1506-1514.
13. Behl, Y.,P. Krothapalli, T. Desta, A. Di Piazza, S. Roy and D.T. Graves, 2008. Diabetes enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am. J. Pathol., 172: 1411-1418.
14. Behl, Y., P. Krothapalli, T. Desta, S. Roy and D.T. Graves, 2009. FOXOl plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes, 58: 917-925.
15. Benjamin, L.E., 2001. Glucose, VEGF-A and diabetic complications. Am. J. Pathol, 158: 1181-1184.
16. Bhadada, S.K., RK. Sahay, V.P. Jyotsna and J.K. Agrawal, 2001. Diabetic neuropathy: Current concepts. Indian Acad.Clm. Med., 2: 305-318.
17. Bonnardel-Phu, E., J.L. Wautier, A.M. Schmidt, C. Avila and E. Vicaut, 1999. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. Diabetes, 48: 2052-2058.
18. Bonney, M., S.J. Hing, A.T. Fung, M.M. Stephens and J.M. Fairchild et al, 1995. Development and progression of diabetic retinopathy: Adolescents at risk. Diabet Med., 12: 967-973.
19. Boulton, A.J.M., F.A. Gries and J.A. Jervell, 1998a. Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabet Med., 15: 508-514.
20. Boulton, M., D. Foreman, G. Williams and D. McLeod, 1998b. VEGF localisation in diabetic retinopathy. Br. J. Ophthalmol., 82: 561-568.
21. Boulton, A.J.M., R.A. Malik, J.S. Arezzo and J.M. Sosenko, 2004. Diabetic somatic neuropathies. Diabetes Care, 27: 1458-1486.
22. Boulton, A.J.M., 2005. Management of diabetic peripheral neuropathy. Clin. Diabetes, 23: 9-15.
23. Boulton, A. J.M., 2007. Medical treatment of symptomatic diabetic neuropathy. Immun. Endocrine Metab. Agents Med. Chem., 7: 79-86.
24. Brown, P.D., S.L. Davies, T. Speake and l.D. Millar, 2004. Molecular mechanisms of cerebrospinal fluid production. Neuroscience, 129: 957-970.
25. Brownlee, M., A. Cerami and H. Vlassara, 1988. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318: 1315-1321.
26. Brownlee, M., 1995. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med., 46: 223-234.
27. Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414: 813-820.
28. Brownlee, M., 2005. The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54: 1615-1625.
29. Bucala, R., K.J. Tracey and A. Cerami, 1991. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 87: 432-438.
30. Burgering, B.M. and G.J. Kops, 2002. Cell cycle and death control. 2002. Long live Forkheads. Trends. Biochem. Sci.,27: 352-360.
31. Cabezas-Cerrato, J., 1998. The prevalence of clinical diabetic polyneuropathy in Spain: A study in primary care and hospital clinic groups. Diabetologia, 41: 1263-1269.
32. Caramori, M.L., P. Fioretto and M. Mauer, 2000. The need for early predictors of diabetic nephropathy risk is albumin excretion rate sufficient. Diabetes, 49: 1399-1408.
33. Carlson Neil, R., 2001. Physiological Psychology. 5th Edn, Allyn and Bacon Press, Boston, MA., pp: 69.
34. Casmiro, M.D., R. Alessandro, F.M. Cacciatore, R. Daidone, F. Calbucci and E. Lugaresi, 1989. Risk factors for the syndrome of ventricular enlargement with gait apraxia. J. Neurol. Neurosurg. Psych., 52: 847-852.
35. Chance, W.W., C. Rhee, C. Yilmaz, 2008. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care, 31: 1596-1601.
36. Chew, E.Y., J.L. Mills, B.E. Metzger, N.A. Remaley and L. Jovanovic-Petersone et al., 1995. Metablolic control and progression of retinopathy: The diabetes in early pregnancy study. National institute of child health and human development diabetes in early pregnancy study. Diabetes Care, 18: 631-637.
37. Chew, E.Y., M.L. Klein, F.L. Ferris, N.A. Remaley and R.P. Murphy et al., 1996. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: The Early Treatment Diabetic Retinopathy Study (ETDRS) report No. 22. Arch. Ophthalmol., 114: 1079-1084.
38. Chibalm, A.V.,M.V. Kovalenko, J.W. Ryder, E. Feraille, H. Wallberg-Henriksson and J.R. Zierath, 2001. Insulin- and glucose-induced phosphorylation of the Na(+),K(+)- adenosine triphosphatase alpha-subunits in rat skeletal muscle. Endocrinology, 142: 3474-3482.
39. Chodobski, A. and J. Szmydynger-Chodobska, 2001. Choroid plexus: Target for polypeptides and site of their synthesis. Microsc. Res. Tech., 52: 65-82.
40. 3ymstoku, 50: 122-125.
41. DCCT Research Group, 1993. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin- dependent diabetes mellitus: The diabetes control and complications trial. N Engl. J. Med., 329: 977-986.
42. DCCT Research Group, 1995. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology, 102: 647-661.
43. DCCT Research Group, 1997. Clustering of complications in families with diabetes in the DCCT. Diabetes, 46: 1829-1839.
44. Dandona, P., A. Aljada, A. Chaudhuri and P. Mohanty, 2004. Endothelial dysfunction, inflammation and diabetes. Rev. Endocrine Metab. Disorders, 5: 189-197.
45. 2+-nitric oxide signalling pathway. Clin. Exp. Pharmacol. Physiol., 32: 771-776.
46. Davis, W.A., M. Knuiman, P. Kendall, V. Grange and T.M. Davis, 2004. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: The fremantle diabetes study. Diabetes Care, 27: 752-757.
47. Dawson, D.W., O.V. Volpert, P. Gillis, S.E. Crawford, H. Xu, W. Benedict and N.P. Bouck, 1999. Pigment epithelium-derived growth factor: A potent inhibitor of angiogenesis. Science, 285: 245-248.
48. De Vnese, A.S., RG. Triton, M. Elger, C.C. Stephan, W. Kriz and N.H. Lameire, 2001. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol, 12: 993-1000.
49. De Zeeuw, D., 2004. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney Int., 66: S2-S6.
50. Degenhardt, T.P., S.R. Thorpe and J.W. Baynes, 1998. Chemical modification of proteins by methylglyoxal. Cell Mol. Biol., 44: 1139-1145.
51. Devi, P. and J. George, 2008. Drug information needs of physicians treating diabetic nephropathy in a tertiary care hospital. Kathmandu Uni. Med. J., 6: 23-27.
52. Dharmalingam, M., 2003. Diabetic retinopathy - risk factors and strategies in prevention. INT. J. Diab. Dev. Countries, 11: 10-13.
53. +-exchanger mRNA levels in ischemic hearts from diabetic rats. Mol. Cell Biochem., 180: 85-93.
54. Egleton, R.D., C. Campos, J. Huber, R. Brown and T. Davis, 2003. Differential effects of diabetes on rat choroids plexus ion transporter expression. Diabetes, 52: 1496-1501.
55. Farina, J., V. Furio, M.J. Fernandez-Acenero and M.A. Muzas, 1995. Nodular fibrosis of the lung in diabetes mellitus. Virchows Arch., 427: 61-63.
56. Feldman, E.L. and A. Vincent, 2004. The prevalence, impact and multifactorial pathogenesis of diabetic peripheral neuropathy. Adv. Stud. Med., 4: 642-649.
57. Feldman, E.L., M.J. Stevens and D.A. Greene, 1997. Pathogenesis of diabetic neuropathy. Clin. Neurosci., 4: 365-370.
58. Flyvbjerg, A., 2000. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia, 43: 1205-1223.
59. Fong, D.S., L.P. Aiello, F.L. Ferris and R. Klein, 2004. Diabetic retinopathy. Diabetes Care, 27: 2540-2553.
60. Forrest, K. Y., R.E. Maser, G. Pambianco, D. J. Becker and T.J. Orchard, 1997. Hypertension as a risk factor for diabetic neuropathy: A prospective study. Diabetes, 46: 665-670.
61. Foster, D.J., P. Ravikumar, D.J. Bellotto, R.H. Linger and C.C.V. Hsia, 2010. Fatty diabetic lung: altered alveolar structure and surfactant protein expression. Am. J. Physiol. Lung Cell Mol. Physiol., 298: 392-403.
62. Fowler, M.J., 2008. Microvascular and macrovascular complications of diabetes. Clin. Diabetes, 26: 77-82.
63. Gabbay, K.H., 1975. Hyperglycemia, polyol metabolism and complications of diabetes mellitus. Annu. Rev. Med., 26: 521-536.
64. Galkina, E. and K. Ley, 2006. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol., 17: 368-377.
65. Galvez, M.I.L., 2009. Rubosixtaurin and other pkc inhibitors in diabetic retinopathy and macular edema. Rev. Curr. Diabetes Rev., 5: 14-17.
66. Garg, S. and R.M. Davis, 2009. Diabetic retinopathy screening update. Clin. Diabetes, 27: 140-145.
67. Geraldes, P., J. Hiraoka-Yamamoto and M. Matsumoto, 2009. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat. Med., 15: 1298-1306.
68. Gerrits, E.G., H.L. Lutgers, N. Kleefstra, R. Graaff and K.H. Groenier et al., 2008. Skin Auto fluorescence, A tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care, 31: 517-521.
69. Gingliano, D., A. Ceriello and G. Pawlisso, 1996. Oxidalive stress and diabetic vascular complications. Diabetes Care, 19: 257-267.
70. Goldman, M.D., 2003. Lung dysfunction in diabetes. Diabetes Care, 26: 1915-1918.
71. Gross, J.L., M.J. de Azevedo, S.P. Silveiro, L.H. Canard, M.L. Caramori and T. Zelmanovitz, 2005. Diabetic nephropathy: Diagnosis, prevention and treatment. Diabetes Care, 28: 164-176.
72. Guvener, N, N.B. Tutuncu, S. Akcay, F. Eyuboglu and A. Gokcel, 2003. Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocr. J., 50: 663-667.
73. Hakvoort, A. and C.E. Johanson, 2000. Growth factor modulation of CSF formation by isolated choroids plexus: FGF-2 vs. TGF-B1. Eur. J. Pediatr. Surg., 10: 44-46.
74. Hammes, H.P., 2005. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab. Res., 37: 39-43.
75. Hendrick, A.L., M.D. Jacqueline, CM. Annette, G. Nejpels and J.H. Robert, 2002. Blood pressure, lipids and obesity are associated with retinopathy. Diabetes Care, 25: 1320-1325.
76. Holl, R.W., G.E. Lange and M. Grahart, 1998. Diabetic retinopathy in pediatric patients with type 1 diabetes: Effect of diabetes duration, prepubertal and pubertal onset of diabetes and metabolic control. J. Pediatr., 132: 790-794.
77. Hsia, C.C., 2002. Recruitment of lung diffusing capacity: update of concept and application. Chest, 122: 1774-1783.
78. Hsia, C.C.W. and P. Raskin, 2008. Lung involvement in diabetes. Does it matter? Diabetes Care, 31: 828-829.
79. Huizinga, M.M. and A. Peltier, 2007. Painful diabetic neuropathy: A management-centered review. Clin. Diabetes, 25: 6-15.
80. Husted, R.F. and D.J. Reed, 1976. Regulation of cerebrospinal fluid potassium by the cat choroids plexus. J. Physiol., 259: 213-221.
81. Husted, R.F. and D.J. Reed, 1977. Regulation of cerebrospinal fluid bicarbonate by the cat choroids plexus. J. Physiol., 267: 411-428.
82. Isotani, H, Y. Nakamura, K. Kameoka, K. Tanaka, K. Furukakawa, H. Kitaoka and N. Ohsawa, 1999. Pulmonary diffusion capacity, serum angiotensinconverting enzyme activity and angiotensin-converting enzyme gene in Japanese non insulin-dependent diabetes mellitus patients. Diabetes Res. Clin Pract, 43: 173-177.
83. Jakobsen, J., G.M. Knudsen and M. Juhler, 1987. Cation permeability of the blood-brain barrier in streptozotocin-diabeticrats. Diabetologia, 30: 409-413.
84. 2+-ATPase activity in rats with streptozocin-induced diabetes: Association with reduced anesthetic requirements. Life Sci., 55: 39-64.
85. Janssen, U., E. Sowa, P. Marchand, J. Floege, A.O. Phillips and H.H. Radekem, 2002. Differential expression of MCP-1 and its receptor CCR2 in glucose primed human mesangial cells. Nephron, 92: 797-806.
86. Jardeleza, M.S.R. and J.W. Miller, 2009. Review of Anti- VEGF therapy in proliferative diabetic retinopathy. Seminars Ophthalmol, 24: 87-92.
87. Johanson, C.E., J. Szmydynger-Chodobska, A. Chodobski, A. Baird, P. McMillan and E.G. Stopa, 1999. Altered formation and bulk absorption of cerebrospinal fluid in FGF-2-induced hydrocephalus. Am. J. Physiol, 277: R263-R271.
88. Kannan, V., 2000. Molecular mechanism of diabetic neuropathy. Int. J. Diab. Dev. Countries, 20: 101-103.
89. Katz, J.S., D.S. Saperstein and G. Wolfe, 2001. Cervicobrachial involvement in diabetic radiculoplexopathy. Muscle Nerve, 24:794-798
90. Keecia, D.K., J.D. Jones and W. Jessica, 2005. Microvascular and macrovascular complications of diabetes mellitus. Am. J. Pharmaceutical Educ, 69: 1-10.
91. Khamaisi, M., B.F. Schrijvers, A.S. De Vriese, I. Raz and A. Flyvbjerg, 2003. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant, 18: 1427-1430.
92. Klarr, S.A., L.J. Ulanski, W. Stummer, J. Xiang, A.L. Betz and R.F. Keep, 1997. The effects of hypo- and hyperkalemia on choroid plexus potassium transport. Brain Res., 758: 39-44.
93. Klein, R., B.E. Klein, S.E. Moss, M. Davis and D. DeMets, 1984. The Wisconsin epidemiological study of diabetic retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol, 102: 520-526.
94. Klein, R., B.E. Klein, S.E. Moss, M.D. Davis and D.L. DeMets, 1989. The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol, 107: 237-243.
95. Klein, B.E.K., S.E. Moss, R. Klein and T.S. Surawicz, 1991. The Wisconsin epidemiologic study of diabetic retinopathy. XLL: Relation-ship of serum cholesterol to retinopathy and hard exudates. Ophthalmology, 98: 1261-1265.
96. Klein, R., B.E. Klein, S.E. Moss and KJ. Cruickshanks, 1995. Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema Ophthalmology. Ophthalmology, 102: 7-16.
97. Klein, R., B.E. Klein, S.E. Moss and KJ. Cruickshanks, 1998. The Wisconsin epidemiologic study of diabetic retinopathy, XVII: The 14-year incidence and progression of diabetic retinopathy and associated risk factors in typel diabetes. Ophthalmology, 105: 1801-1815.
98. Klein, R., A.R. Sharrett, B.E. Klein, S.E. Moss and A.R. Folsom et al, 2002. The association of atherosclerosis, vascular risk factors and retinopathy in adults with diabetes: The atherosclerosis risk in communities study. Ophthalmology, 109: 1225-1234.
99. Knudsen, G.M., J. Jakobsen, M. Juhler and O.B. Paulson, 1986. Decreased blood-brain barrier permeability to sodium in early experimental diabetes. Diabetes, 35: 1371-1373.
100. Kohner, E.M., I.M. Stratton, S. J. Aldington, R.R. Holman, D.R. Matthews and UK Prospective Diabetes Study (UKPDS) Group, 2001. Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabetes Med., 18: 178-184.
101. Kordonouri, O., T.H. Danne and W. Hopfenmuller, 1996. Lipid profiles and blood pressure: Are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin dependent diabetes mellitus?. Acta Paediatr., 85: 43-48.
102. Koya, D.and G.L. King, 1998. Protein kinase C activation and the development of diabetic complications. Diabetes, 47: 859-866.
103. Kramerov, A.A., M. Saghizadeh, H. Pan, A. Kabosova and M. Montenarh et al, 2006. Expression of protein kinase CK2 in astroglial cells of normal and neovascularizedretina. Am. J.Pathol., 168:1722-1736.
104. Krauss, J.K., J.P. Regel, W. Vach, D.W. Droste, J.J. Borremans and T. Mergner, 1996. Vascular risk factors and arteriosclerotic disease in idiopathic normalpressure hydrocephalus of the elderly. Stroke, 27: 24-29.
105. Kukidome, D., T. Nishikawa, K. Sonoda, K. Imoto and K. Fujisawa et al., 2006. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes, 55: 120-127.
106. + ATPase activity in kidney, brain and erythrocyte membrane in alloxan diabetic rats. Indian J. Exp. Biol., 30: 26-32.
107. Layne, J., S. Yip and RB. Crook, 2001. Down-regulation of Na-K-Cl cotransport by protein kinase C is mediated by protein phosphatase 1 in pigmented ciliary epithelial cells. Exp. Eye Res., 72: 371-379.
108. Levy, J., L.V. Avioli, M.L. Roberts and J.R. Gavin, 1986. (Na+ -K+)-ATPase activity in kidney basolateral membranes of non insulin dependent diabetic rats. Biochem. Biophys. Res. Commun., 139: 1313-1319.
109. Litonjua, A.A., R. Lazarus, D. Sparrow, D. Demolles and S.T. Weiss, 2005. Lung function in type 2 diabetes: The normative aging study. Respir. Med., 99: 1583-1590.
110. Lteif, A.A., K. Han and K.J. Mather, 2005. Obesity, insulin resistance and the metabolic syndrome: Determinants of endothelial dysfunction in whites and blacks. Circulation, 112: 32-38.
111. Makita, Z., S. Radoff, E.J. Rayfield, Z. Yang andE. Skolmk et al, 1991. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl. J. Med., 325: 836-842.
112. McKeeve, T.M., P.J. Weston, R. Hubbard and A. Fogarty, 2005. Lung function and glucose metabolism: An analysis of data from the third national health and nutrition examination survey. Am. J. Epidemiol., 161: 546-556.
113. Michea, L., V. Irribarra, LA. Goecke and E.T. Marusic, 2001. Reduced Na-K: Pump but increased Na-K-2C1 cotransporter in aorta of streptozotocin-induced diabetic rat. Am. J. Physiol, 280: H851-H858.
114. Mizutani, M., T.S. Kern and M. Lorenzi, 1996. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest, 97: 2883-2890.
115. Mohamed, Q., M.C. Gillies and T.Y. Wong, 2007. Management of diabetic retinopathy: A systematic review. JAMA., 298: 902-916.
116. Monnier, V.M., V. Vishwanath and K.E. Frank, 1986. Relation between complication of type 1 diabetes mellitus and collagen linked fluroscence. N Engl. J. Med., 314: 403-408.
117. Mori, H., M. Okubo, M. Okamura, K. Yamane and S. Kado et al, 1992. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Intern. Med., 31: 189-193.
118. Murphy, V.A., Q.R. Smith and S.I. Rapoport, 1986. Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia. J. Neurochem., 47: 1735-1741.
119. Nakamura, M., A. J. Barber, D.A. Antonetti, K.F. LaNoue, K.A. Robinson, M.G. Buse and T.W. Gardner, 2001. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J. Biol. Chem., 276: 43748-43755.
120. Nerlich, A.G., U. Sauer, V. Kolm-Litty, E. Wagner, M. Koch and E.D. Schleicher, 1998. Expression of glutamine: Fructose-6-phosphate amidotransferase in human tissues: Evidence for high variability and distinct regulation in diabetes. Diabetes, 47: 170-178.
121. Nilsson, C, M. Lindvall-Axelsson and C. Owman, 1992. Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Rev., 17: 109-138.
122. Niranjan, V., D.G. McBrayer, L.C. Ramirez, P. Raskin and C.C.W. Hsia, 1997. Glycemic control and cardiopulmonary function in patients with insulin- dependent diabetes mellitus. Am. J. Med., 103: 504-513.
123. Nishikawa, T., D. Edelstein, X.L. Du, S. Yamagishi and T. Matsumura et al., 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404: 787-790.
124. Nishimura, C, T. Saito, T. Ito, Y. Omori and T. Tanimoto, 1994. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia, 37: 328-330.
125. Nishizuka, Y., 1992. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science, 258: 607-614.
126. Obrosova, I.G., L. Fathallah and M.J. Stevens, 2001. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp. Neurol., 172: 211-219.
127. Okada, S., K. Shikata, M. Matsuda, D. Ogawa and H. Usui et al., 2003. Intercellular adhesion molecule-1- deficient mice are resistant against renal injury after induction of diabetes. Diabetes, 52: 2586-2593.
128. Olsen, B.S., A.K. Sjolie, P. Hougaard, J. Johannesen and K. Borch-Johnsen et al., 2000. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish study group of diabetes in childhood. J. Diabetes Complications, 14: 295-300.
129. Papadogeorgos, N.O., M. Bengtsson and M. Kalani, 2009. Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. Vase Health Risk Manage., 5: 893-899.
130. Paques, M., P. Massin and A. Gaudric, 1997. Growth factors and diabetic retinopathy. Diabetes Metab., 23: 125-130.
131. Pardianto, G., 2005. Understanding diabetic retinopathy. Mimbar llmiah Oftalmologi Indonesia, 2: 65-66.
132. Park, C.W., J.H. Kim, J.H. Lee, Y.S. Kim and H.J. Ahn et al., 2000. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NFkappa B-dependent. Diabetologia, 43: 1544-1553.
133. Pena, R.A., J. A. Jerdan and G.M. Glaser, 1994. Effects of TGF-beta and TGF-beta neutralizing antibodies on fibroblast-induced collagen gel contraction: Implications for proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci., 35: 2804-2808.
134. Peppa, M., J. Uribarri and H. Vlassara, 2003. Glucose, advanced glycation end products and diabetes complications: What is new and what works. Clin. Diabetes, 21: 186-187.
135. + exchange in cardiac sarcolemmal vesicles isolated from diabetic rats. Am. J. Physiol., 258: 255-261.
136. Plante, G.E., M. Chakir, S. Lehoux and M. Lortie, 1995. Disorders of body fluid balance: Anew look into the mechanisms of disease. Can. J. Cardiol., 11: 788-802.
137. Plotkin, M.D., M.R. Kaplan, L.N. Peterson, S.R. Gullans, S.C. Hebert and E. Delpire, 1997. Expression of the Na+-K+-2C1- cotransporter BSC2 in the nervous system. Am. J. Physiol., 272: C173-C183.
138. Rajagopal, J., A.G. Kamath G.G. Kamath and N. Solanki, 2009. Foveal neovascularisation in diabetic retinopathy: Case report and review of literature. Int. Ophtalmol, 10.1007/sl 0792-009-9317-8
139. Rajbhandari, S.M. and M.K. Piya, 2005. A brief review on the pathogenesis of human diabetic neuropathy: Observation and postulations. Int. J. Diabet. Metabolism., 13: 135-140.
140. Ramirez, L.C, A. Dal Nogare, C.C.W. Hsia, C. Arauz, S. Strowig, L. Schnurrbreen and P. Raskin, 1991. Relationship between diabetes control and pulmonary function in insulin dependent diabetes mellitus. Am. J. Med., 91: 371-376.
141. Ritz, E., 1999. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am. J. Kidney Disease, 34: 795-808.
142. Rossing, P., K. Rossing, P. Jacobsen and H.H. Parving, 1995. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes, 44: 739-743.
143. Russell, J.W., A.J. Windebank, A. Schenone and E.L. Feldman, 1998. Insulin-like growth factor-1 prevents apoptosis in neurons after growth factor withdrawal. J. Neurobiol, 36: 455-467.
144. Russell, J.W., D. Golovoy, A.M. Vincent P- Mahendru, J.A. Olzmann, A. Mentzer and E.L. Feldman, 2002. High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J., 16: 1738-1748.
145. Sasase, T., 2006. PKC - A target for treating diabetic complications. Drugs Fut, 31: 503-503.
146. Schleicher, E.D. and C. Weigert, 2000. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int., 88: 12-18.
147. Schmieder, RE., S. Martin, G.E. Lang, P. Bramlage and M. Bohm, 2009. Angiotensin blockade to reduce microvascular damage in diabetes mellitus. Dtsch Arztebl Int, 106: 556-562.
148. Schwarzenberg, S.J., W. Thomas, T.W. Olsen, T. Grover, D. Walk, C. Milla and A. Moran, 2007. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care, 30: 1056-1061.
149. Segal, M.B., 1993. Extracellular and cerebrospinal fluid. J. Inherit. Metabol. Dis., 16: 617-638.
150. Selvin, E., S. Marinopoulos, G. Berkenblit, T. Rami and F.L. Brancati et al., 2004. Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med., 141: 421-431.
151. Shestakova, M.V., T.V. Kochemasova, V.A. Gorelysheva and T.V. Osipova et al, 2002. [The role of adhesion molecules (ICAM-1 and E-selectin) in development of diabetic microangiopathies]. Terapevticheskii Arkhiv, 74: 24-27.
152. Shiba, T., T. Inoguchi, J.R. Sportsman, W.F. Heath, S. Bursell and G.L. King, 1993. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol., 265: 783-793.
153. Shichiri, M., H. Kishikawa, Y. Ohkubo and N. Wake, 2000. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 23: 21-29.
154. Siczkowski, M., J.E. Davies, F.P. Sweeney, A. Kofoed-Enevoldsen and L.L. Ng, 1995. NaVFf exchanger isoform-1 abundance in skin fibroblasts of type I diabetic patients with nephropathy. Metabolism, 44: 791-795.
155. Simmons, Z. and E.L. Feldman, 2002. Update on diabetic neuropathy. Curr. Opin Neurol., 15: 595-603.
156. Snow, V., K.B. Weiss and C. Mottur-Pilson, 2003. Clinical efficacy assessment subcommittee of the american college of physicians: The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann. Int. Med., 138: 587-592.
157. Spranger, J., R. Meyer-Schwickerath, M. Klein, H. Schatz and A. Pfeiffer, 1999. Deficient activation and different expression of transforming growth factor-B isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp. Clin. Endocrinol., 107: 21-28.
158. Stevensa, M.J., E.L. Feldmanb and D.A. Greenea, 2009. The aetiology of diabetic neuropathy: The combined roles of metabolic and vascular defects. J. Diabetes UK., 12: 566-579.
159. Sumiyoshi, K., C. Kawata, K. Shikata and H. Makino, 2010. Influencing factors for dietary behaviors of patients with diabetic nephropathy. Acta Med. Okayama, 64: 39-47.
160. Sweeney, G., W. Niu, V.A. Canfield, R. Levenson and A. Klip, 2001. Insulin increases plasma membrane content and reduces phosphorylation of Na+-K+ pump alpha(l)-subunit in HEK-293 cells. Am. J. Physiol, 281: 1797-1803.
161. Tarnow, L., C. Gluud and H.H. Parving, 1998. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant, 13:1125-1130.
162. Tarnow, L., P. Rossing, F.S. Nielsen, J.A. Fagerudd, O. Poirier and H.H. Parving, 2000. Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 23: 30-33.
163. +-ATPase and changes in ATP hydrolysis, monovalent cation affinity and K+ occlusion in diabetic and galactosemic rats. Diabetes, 39: 1472-1478.
164. Tehranipour, M., R. Haeri, M.B. Rassouli, K. Parivar and A. Rahimi, 2007. Determanation of the cerebrospinal fluid electrolytes alteration in the developing rats born from diabetic mothers. J. Biol. Sci., 7: 969-972.
165. Tehranipour, M., M. Behnam Rassouli and A. Rahimi, 2008. Maternal diabetes proliferate the choroid plexus and enlarge the lateral ventricle in brain of newborn rats. J. Biol. Sci., 15: 147-147.
166. + pump activity in diabetic rabbit carotid artery: reversal by aldose reductase inhibition. Am. J. Physiol, 265: 1189-1194.
167. Thomas, P.K. and D.R. Tomlinson, 1993. Diabetic and Hypoglycemic Neuropathy. In: Peripheral Neuropathy, Dyck, P.J., P.K. Thomas, J.W. Griffin, P.A. Low and J.F. Poduslo (Eds.). 3rd Edn., W.B. Saunders, Philadelphia, pp: 1219-1250.
168. Tomlinson, D.R., 1989. Polyols and myointositol in diabetic neuropathy of mice and men. Mayo Clin. Proc, 64: 1030-1030.
169. UK Prospective Diabetes Study Group, 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317: 703-713.
170. Van Leiden, H.A., J.M. Dekker, A.C. Moll, G. Nijpels and R.J. Heine et al., 2002. Blood pressure, lipids and obesity are associated with retinopathy: The hoorn study. Diabetes Care, 25: 1320-1325.
171. Vincent, A.M. and E.L. Feldman, 2004. New insights into the mechanisms of diabetic neuropathy. Rev. Endocrine Metabolic Disorders, 5: 227-236.
172. Vincent A.M., J.A. Olzmann, M. Brownlee, W.I. Sivitz and J.W. Russell, 2004. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes, 53: 726-734.
173. Vinik, A.I. and T. Erbas, 2001. Recognizing and treating diabetic autonomic neuropathy. Cleveland Clinic J. Med., 68: 928-944.
174. Vlassara, H., M. Brownlee and A. Cerami, 1983. Excessive non enzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes, 32: 670-674.
175. Vracko, R., D. Thorning and T.W. Huang, 1979. Basal lamina of alveolar epithelial and capillaries. Quantitative changes with aging and diabetes melhtus. Am. Rev. Respir. Dis., 120: 973-983.
176. Watkms, P.J., 2003. ABC of diabetes Retinopathy. BMJ., 326: 924-926.
177. Wautier, J.L. and P.J. Guillausseau, 2001. Advanced glycation end products, their receptors and diabetic angiopathy. Diabete Metab., 27: 535-542.
178. Ways, D.K. and M.J. Sheetz, 2000. The role of protein kinase C in the development of the complications of diabetes. VitamHorm, 60: 149-193.
179. Weaver, C.E., P.N. Mc-Millan, J.A. Duncan, E.G. Stopa and C.E. Johanson, 2004. Hydrocephalus disorders: Their biophysical and neuroendocrine impact on the choroid plexus epithelium. Adv. Mol. Cell Biol., 31: 269-293.
180. Weir, D.C., P.E. Jennings, M.S. Hendy, A.H. Barnett and P.S. Burge, 1998. Transfer factor for carbon monoxide in patients with diabetes with and without microangiopathy. Thorax, 43: 725-726.
181. Weisbrod, D. and C. Schwartz, 2009. A review of diabetic retinopathy. Ophthalmol. Rounds, Vol. 7.
182. Welles, R.V., 2003. Diabetic polyneuropathy: A review of the need for early diagnosis and treatment. Diabetes Symposium, 72: 13-17.
183. Weynand, B., A. Jonckheere and A. Frans, 1999. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration, 66: 14-19.
184. Wild, S., G. Roglic, A. Green, R Sicree and H. King, 2004. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care., 27: 1047-1053.
185. Winegrade, A.I., 1987. Does a common mechanism induce the diverse complications of diabetes?. Diabetes, 36: 396-406.
186. Wolf, G., 2004. New insights into the pathophysiology of diabetic nephropathy: From haemodynamics to molecular pathology. Eur. J. Clin. Invest, 34: 785-796.
187. Wong, T.Y., G. Liew, R.J. Tapp, M.I. Schmidt and J.J. Wang et al., 2008. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 371: 700-702.
188. Wright E.M., 1978. Transport processes in the formation of the cerebrospinal fluid. Rev. Physiol. Pharmacol., 83: 1-34.
189. Yagihashi, S., S.I. Yamagishi and R.I. Wada, 2001. Neuropathy in diabetic mice over expressing human aldose reductase and effects of aldose reductase inhibitor. Brain, 124: 2448-2458.
190. Yen, V., 2010. Principles of Diabetes Mellitus. Part 8. Springer US, Canada, pp: 749-753.
191. Young, B.A., C. Maynard and E.J. Boyko, 2003. Racial differences in diabetic nephropathy, cardiovascular disease and mortality in a national population of veterans. Diabetes Care, 26: 2392-2399.
192. Zhang, D.X. and D.D. Gutterman, 2007. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am. J. Physiol. Heart Circ Physiol., 292: 2023-2031.